Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.82 |
| ▸ | APAF1 | O14727 | 2/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buparvaquone SCHEMBL22978 | 1.00 | CDC25B (0.82) | CDC25BAPAF1TDP2GLARAB9A | |
| Buparvaquone SCHEMBL11030015 | 1.00 | CDC25B (0.82) | CDC25BAPAF1TDP2GLARAB9A | |
| Buparvaquone SCHEMBL30634020 | 1.00 | CDC25B (0.82) | CDC25BAPAF1TDP2GLARAB9A | |
| Buparvaquone SCHEMBL9598809 | 1.00 | CDC25B (0.82) | CDC25BAPAF1TDP2GLARAB9A | |
| Buparvaquone SCHEMBL23064136 | 0.97 | CDC25B (0.79) | CDC25BAPAF1TDP2GLARAB9A | |
| Buparvaquone SCHEMBL18740425 | 0.94 | CDC25B (0.73) | CDC25BAPAF1TDP2GLARAB9A | |
| SCHEMBL28771087 | 0.90 | CDC25B (1.00) | CDC25BAPAF1TDP2GLARAB9A | |
| Buparvaquone SCHEMBL8200585 | 0.89 | CDC25B (0.66) | CDC25BAPAF1TDP2GLARAB9A | |
| SCHEMBL11066443 | 0.88 | CDC25B (0.65) | CDC25BAPAF1TDP2RAB9APOLB | |
| SCHEMBL11066448 | 0.88 | CDC25B (0.65) | CDC25BAPAF1TDP2RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117205190-A | Application of buparvaquone in preparation of medicines for resisting Dabiebanda virus infection | 中国人民解放军海军军医大学 | 2023-12-12 | — | — | CN | disclosed |
| US-20220265566-A1 | ATOVAQUONE NANOPARTICULATE COMPOSITIONS | TULEX PHARMACEUTICALS INC (US) | 2022-08-25 | — | — | US | disclosed |
| CN-110734368-B | Preparation method of buparvaquone | 新发药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220218632-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-07-14 | — | — | US | disclosed |
| US-11384371-B2 | Hydroxylation of branched aliphatic or aromatic substrates employing the amycolatopsis lurida cytochrome P450 | HYPHA DISCOVERY LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| US-20220144894-A1 | ANTIPLASMODIAL COMPOUNDS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3345594-B1 | SOLUBILIZED FLAVONOID COMPOSITION | TECH INVESTMENTS LC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210230642-A1 | HYDROXYLATION TECHNIQUES | HYPHA DISCOVERY LTD. (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200115415-A1 | ANTIPLASMODIAL COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2020-04-16 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2012054090-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS | API GENESIS, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218632-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, CDK4, PIN1 | CDC25B 108/4885APAF1 2489/4885TDP2 2178/4885 |
| US-20220265566-A1 | ATOVAQUONE NANOPARTICULATE COMPOSITIONS | RECQL, ATIC, POLQ | CDC25B 734/4885APAF1 2778/4885TDP2 2874/4885 |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | CDC25B 1078/4885APAF1 1331/4885TDP2 1188/4885 |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | CDC25B 1078/4885APAF1 1331/4885TDP2 1188/4885 |
| US-20220144894-A1 | ANTIPLASMODIAL COMPOUNDS | MGST3, G6PD, GPX4 | CDC25B 1978/4885APAF1 627/4885TDP2 1900/4885 |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | CDC25B 1078/4885APAF1 1331/4885TDP2 1188/4885 |
| US-20200115415-A1 | ANTIPLASMODIAL COMPOUNDS | MGST3, G6PD, GPX4 | CDC25B 1978/4885APAF1 627/4885TDP2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.